Loading…
This entity appears on both sides of lobbying disclosures. The firm tab shows registrant-reported income; the client tab shows client-reported lobbying spend. Contract awards are separate and are not included here.
Lobbying Spend
$4.9M
Filings
33
Firms Hired
1
Active Period
2017–2024
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
BLOCKING Act of 2019
2020 · fourth_quarter · Firm: GLENMARK PHARMACEUTICALS USA
HR 938, BLOCKING Act, issues related to pharmaceutical manufacturing supply chain
Client expense: $135,000 · Firm income: —
Matched citations: HR 938
HR 938, BLOCKING Act, issues related to pharmaceutical manufacturing supply chain
Client expense: $277,000 · Firm income: —
Matched citations: HR 938
Protecting Consumer Access to Generic Drugs Act of 2019
2020 · second_quarter · Firm: GLENMARK PHARMACEUTICALS USA
S. 64, Preserve Access to Affordable Generics and Biosimilars Act HR 938, BLOCKING Act HR 1499, Protecting Consumer Access to Generic Drugs Act of 2019 HR 1506, FAIR Generics Act
Client expense: $135,000 · Firm income: —
Matched citations: HR 1499
S. 64, Preserve Access to Affordable Generics and Biosimilars Act HR 938, BLOCKING Act HR 1499, Protecting Consumer Access to Generic Drugs Act of 2019 HR 1506, FAIR Generics Act
Client expense: $135,000 · Firm income: —
Matched citations: HR 1506
BLOCKING Act of 2019
2020 · second_quarter · Firm: GLENMARK PHARMACEUTICALS USA
S. 64, Preserve Access to Affordable Generics and Biosimilars Act HR 938, BLOCKING Act HR 1499, Protecting Consumer Access to Generic Drugs Act of 2019 HR 1506, FAIR Generics Act
Client expense: $135,000 · Firm income: —
Matched citations: HR 938
Preserve Access to Affordable Generics and Biosimilars Act
2020 · second_quarter · Firm: GLENMARK PHARMACEUTICALS USA
S. 64, Preserve Access to Affordable Generics and Biosimilars Act HR 938, BLOCKING Act HR 1499, Protecting Consumer Access to Generic Drugs Act of 2019 HR 1506, FAIR Generics Act
Client expense: $135,000 · Firm income: —
Matched citations: S. 64
Protecting Consumer Access to Generic Drugs Act of 2019
2020 · first_quarter · Firm: GLENMARK PHARMACEUTICALS USA
S. 64, Preserve Access to Affordable Generics and Biosimilars Act HR 938, BLOCKING Act HR 1499, Protecting Consumer Access to Generic Drugs Act of 2019 HR 1506, FAIR Generics Act
Client expense: $350,000 · Firm income: —
Matched citations: HR 1499
S. 64, Preserve Access to Affordable Generics and Biosimilars Act HR 938, BLOCKING Act HR 1499, Protecting Consumer Access to Generic Drugs Act of 2019 HR 1506, FAIR Generics Act
Client expense: $350,000 · Firm income: —
Matched citations: HR 1506
S. 64, Preserve Access to Affordable Generics and Biosimilars Act HR 938, BLOCKING Act HR 1499, Protecting Consumer Access to Generic Drugs Act of 2019 HR 1506, FAIR Generics Act
Client expense: $350,000 · Firm income: —
Matched citations: HR 938
Preserve Access to Affordable Generics and Biosimilars Act
2020 · first_quarter · Firm: GLENMARK PHARMACEUTICALS USA
S. 64, Preserve Access to Affordable Generics and Biosimilars Act HR 938, BLOCKING Act HR 1499, Protecting Consumer Access to Generic Drugs Act of 2019 HR 1506, FAIR Generics Act
Client expense: $350,000 · Firm income: —
Matched citations: S. 64
Protecting Consumer Access to Generic Drugs Act of 2019
2019 · fourth_quarter · Firm: GLENMARK PHARMACEUTICALS USA
S. 64, Preserve Access to Affordable Generics and Biosimilars Act HR 938, BLOCKING Act HR 1499, Protecting Consumer Access to Generic Drugs Act of 2019 HR 1506, FAIR Generics Act
Client expense: $135,000 · Firm income: —
Matched citations: HR 1499
S. 64, Preserve Access to Affordable Generics and Biosimilars Act HR 938, BLOCKING Act HR 1499, Protecting Consumer Access to Generic Drugs Act of 2019 HR 1506, FAIR Generics Act
Client expense: $135,000 · Firm income: —
Matched citations: HR 1506
BLOCKING Act of 2019
2019 · fourth_quarter · Firm: GLENMARK PHARMACEUTICALS USA
S. 64, Preserve Access to Affordable Generics and Biosimilars Act HR 938, BLOCKING Act HR 1499, Protecting Consumer Access to Generic Drugs Act of 2019 HR 1506, FAIR Generics Act
Client expense: $135,000 · Firm income: —
Matched citations: HR 938
Preserve Access to Affordable Generics and Biosimilars Act
2019 · fourth_quarter · Firm: GLENMARK PHARMACEUTICALS USA
S. 64, Preserve Access to Affordable Generics and Biosimilars Act HR 938, BLOCKING Act HR 1499, Protecting Consumer Access to Generic Drugs Act of 2019 HR 1506, FAIR Generics Act
Client expense: $135,000 · Firm income: —
Matched citations: S. 64
Protecting Consumer Access to Generic Drugs Act of 2019
2019 · third_quarter · Firm: GLENMARK PHARMACEUTICALS USA
S. 64, Preserve Access to Affordable Generics and Biosimilars Act HR 938, BLOCKING Act HR 1499, Protecting Consumer Access to Generic Drugs Act of 2019 HR 1506, FAIR Generics Act
Client expense: $383,000 · Firm income: —
Matched citations: HR 1499
S. 64, Preserve Access to Affordable Generics and Biosimilars Act HR 938, BLOCKING Act HR 1499, Protecting Consumer Access to Generic Drugs Act of 2019 HR 1506, FAIR Generics Act
Client expense: $383,000 · Firm income: —
Matched citations: HR 1506
S. 64, Preserve Access to Affordable Generics and Biosimilars Act HR 938, BLOCKING Act HR 1499, Protecting Consumer Access to Generic Drugs Act of 2019 HR 1506, FAIR Generics Act
Client expense: $383,000 · Firm income: —
Matched citations: HR 938
Preserve Access to Affordable Generics and Biosimilars Act
2019 · third_quarter · Firm: GLENMARK PHARMACEUTICALS USA
S. 64, Preserve Access to Affordable Generics and Biosimilars Act HR 938, BLOCKING Act HR 1499, Protecting Consumer Access to Generic Drugs Act of 2019 HR 1506, FAIR Generics Act
Client expense: $383,000 · Firm income: —
Matched citations: S. 64
Protecting Consumer Access to Generic Drugs Act of 2019
2019 · second_quarter · Firm: GLENMARK PHARMACEUTICALS USA
S. 64, Preserve Access to Affordable Generics and Biosimilars Act HR 938, BLOCKING Act HR 1499, Protecting Consumer Access to Generic Drugs Act of 2019 HR 1506, FAIR Generics Act
Client expense: $135,000 · Firm income: —
Matched citations: HR 1499
S. 64, Preserve Access to Affordable Generics and Biosimilars Act HR 938, BLOCKING Act HR 1499, Protecting Consumer Access to Generic Drugs Act of 2019 HR 1506, FAIR Generics Act
Client expense: $135,000 · Firm income: —
Matched citations: HR 1506
BLOCKING Act of 2019
2019 · second_quarter · Firm: GLENMARK PHARMACEUTICALS USA
S. 64, Preserve Access to Affordable Generics and Biosimilars Act HR 938, BLOCKING Act HR 1499, Protecting Consumer Access to Generic Drugs Act of 2019 HR 1506, FAIR Generics Act
Client expense: $135,000 · Firm income: —
Matched citations: HR 938
Preserve Access to Affordable Generics and Biosimilars Act
2019 · second_quarter · Firm: GLENMARK PHARMACEUTICALS USA
S. 64, Preserve Access to Affordable Generics and Biosimilars Act HR 938, BLOCKING Act HR 1499, Protecting Consumer Access to Generic Drugs Act of 2019 HR 1506, FAIR Generics Act
Client expense: $135,000 · Firm income: —
Matched citations: S. 64
Protecting Consumer Access to Generic Drugs Act of 2019
2019 · first_quarter · Firm: GLENMARK PHARMACEUTICALS USA
S. 64, Preserve Access to Affordable Generics and Biosimilars Act HR 938, BLOCKING Act HR 1499, Protecting Consumer Access to Generic Drugs Act of 2019 HR 1506, FAIR Generics Act
Client expense: $359,421 · Firm income: —
Matched citations: HR 1499
S. 64, Preserve Access to Affordable Generics and Biosimilars Act HR 938, BLOCKING Act HR 1499, Protecting Consumer Access to Generic Drugs Act of 2019 HR 1506, FAIR Generics Act
Client expense: $359,421 · Firm income: —
Matched citations: HR 1506
S. 64, Preserve Access to Affordable Generics and Biosimilars Act HR 938, BLOCKING Act HR 1499, Protecting Consumer Access to Generic Drugs Act of 2019 HR 1506, FAIR Generics Act
Client expense: $359,421 · Firm income: —
Matched citations: HR 938
Source: Senate LDA